Trial Profile
An open label, single institution, phase II study of the mTOR inhibitor temsirolimus in unresectable and/or metastatic renal cell carcinoma (RCC) in patients previously treated with both cytokines and one or more tyrosine kinase inhibitor, The TeRCC study.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 31 Oct 2011
Price :
$35
*
At a glance
- Drugs Temsirolimus (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms TeRCC
- 10 Aug 2011 New trial record